Please assess the completion status of the following clinical trial:

Trial Title: Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically diagnosed peripheral sensory neuropathy defined as:~* Greater than Grade 1 peripheral sensory neuropathy using the CTCAE v5.0 grading scale~  * Grade 1 Asymptomatic~ * Grade 2 Moderate symptoms; limiting instrumental activities of daily living (ADL)~ * Grade 3 Severe symptoms; limiting self-care ADL~ * Grade 4 Life-threatening consequences; urgent intervention indicated~* Have a baseline chemotherapy-induced peripheral neuropathy (CIPN) patient reported outcome (PRO) total sensory score ≥ 24.3 on a 19 to 76 scale using the European Organization for Research and Treatment of Cancer Quality of Life-CIPN20 Questionnaire (EORTC QLQ-CIPN-20)~* Have a CIPN-related neuropathic pain score ≥ 4 on a 0 to 10 scale using the Brief Pain Inventory-Short Form (BPI-SF) item 5~* Will not have used any nicotine or tobacco products (eg, cigarettes, electronic cigarettes, smokeless tobacco, or other nicotine replacement therapies) within 14 days prior to study treatment start date~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~* Not currently receiving any chemotherapy~* Have previously received platinum- and/or taxane-based chemotherapy treatments and have persistent pain at least 3 months after completion of treatments.~* Willing and able to comply with study procedures and visit schedule.~* Willing to abstain from all tobacco/nicotine product use during study treatment and 30-day follow-up period.~* Ability to self-apply or have the patch applied at home daily.~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* History of pre-existing peripheral sensory neuropathies related to the following:~  * Autoimmune disease~ * B12/folate deficiency~ * Diabetes Mellitus~ * Human immunodeficiency virus (HIV)~ * Hyper/hypothyroidism~ * Monoclonal gammopathy of undetermined significance or multiple myeloma~* History of receiving other types of neurotoxic chemotherapy drugs (eg, vinca alkaloids, bortezomib, thalidomide)~* Current or prior pheochromocytoma~* History of or active or clinically significant cardiac disease including any of the following:~  * Unstable angina (eg, anginal symptoms at rest) or onset of angina within 3 months prior to initiating study treatment~ * Myocardial infarction diagnosed within 6 months prior to initiating study treatment~ * Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers~* New York Heart Association (NYHA) class III or IV congestive heart failure~* Poorly controlled high or low blood pressure defined as:~  * Systolic blood pressure (SBP) ≥ 140; Diastolic blood pressure (DBP) ≥ 90~ * SBP ≤ 90; DBP ≤ 60~* Regular use of the following medications:~  * Varenicline~ * Bupropion (ie, bupropion hydrochloride sustained release)~* Women will be excluded if they are breastfeeding or are pregnant (by urinalysis) within 14 days prior to the start of nicotine transdermal patch administration.~* Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nicotine Transdermal Patch Administration (Type: EXPERIMENTAL): Each patient will complete two 14-day treatment conditions, for 7 mg nicotine transdermal patch administration with a washout period in between (≥ 14 days and up to 21 days), then 14 mg nicotine transdermal patch administration (14 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).